GITumorPanel
TARGET AUDIENCE
This activity is intended for medical oncologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of colorectal, gastric and pancreatic cancer. OVERVIEW OF ACTIVITY Two noncolorectal GI tumors in particular — gastric and pancreatic cancer — have witnessed several recent advances that have drastically altered current treatment considerations and approaches. As such, educational opportunities relevant to the clinical management of colorectal, gastric and pancreatic cancers are essential for medical oncologists responsible for delivering comprehensive care. These video proceedings from a CME symposium held during the 2015 ASCO Annual Meeting feature discussions with leading researchers with an expertise in colorectal, gastric and pancreatic cancer regarding actual patient cases and related clinical research findings. By providing information on the latest research developments and their potential application to routine practice, this activity is designed to not only improve clinicians’ knowledge of recent data related to the rapidly evolving GI cancer treatment landscape but also to provide them with practical perspectives to help them become better and more effective caregivers. LEARNING OBJECTIVES
ACCREDITATION STATEMENT CME credit is no longer available for this issue CREDIT DESIGNATION STATEMENT CME credit is no longer available for this issue HOW TO USE THIS CME ACTIVITY CME credit is no longer available for this issue CONTENT VALIDATION AND DISCLOSURES FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Peter C Enzinger, MD Consulting Agreements: Amgen Inc, Five Prime Therapeutics Inc, Pfizer Inc, Sirtex Medical Ltd, Taiho Oncology Inc. Axel Grothey, MD Contracted Research: Bayer HealthCare Pharmaceuticals, Eisai Inc, Genentech BioOncology, Lilly, Pfizer Inc, Sanofi. J Randolph Hecht, MD Consulting Agreements: Amgen Inc, Genentech BioOncology, Sanofi. Eileen M O’Reilly, MD Consulting Agreements: Abbott Laboratories, Aduro Biotech, Amgen Inc, Astellas Scientific and Medical Affairs Inc, Celgene Corporation, Celsion Corporation, Chugai Pharmaceutical Co Ltd, Cipla Ltd, EntreMed Inc, Exelixis Inc, Genentech BioOncology, Gilead Sciences Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, IntegraGen, Jennerex Inc, Lilly, MedImmune Inc, Momenta Pharmaceuticals Inc, Novartis Pharmaceuticals Corporation, Roche Laboratories Inc, Sanofi, Silenseed Ltd, Vicus Therapeutics; Contracted Research: Abbott Laboratories, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Exelixis Inc, Genentech BioOncology, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Momenta Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Novartis Pharmaceuticals Corporation, OncoMed Pharmaceuticals Inc, Onyx Pharmaceuticals, an Amgen subsidiary, Polaris Group, Roche Laboratories Inc, Vicus Therapeutics. Philip A Philip, MD, PhD Advisory Committee: Celgene Corporation, Halozyme Therapeutics, Novartis Pharmaceuticals Corporation; Consulting Agreement: Merck; Contracted Research: Bayer HealthCare Pharmaceuticals, Celgene Corporation, Karyopharm Therapeutics, Lilly, Novartis Pharmaceuticals Corporation; Speakers Bureau: Amgen Inc, Bayer HealthCare Pharmaceuticals, Celgene Corporation, Genentech BioOncology, Novartis Pharmaceuticals Corporation, Sanofi. Eric Van Cutsem, MD, PhD Consulting Agreements: Bayer HealthCare Pharmaceuticals, Lilly; Research Grants: Amgen Inc, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Merck Serono, Novartis Pharmaceuticals Corporation, Roche Laboratories Inc, Sanofi. MODERATOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Amgen Inc, Astellas Scientific and Medical Affairs Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, ImmunoGen Inc, Incyte Corporation, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Medivation Inc, Merck, Myriad Genetic Laboratories Inc, NanoString Technologies, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Teva Oncology, Tokai Pharmaceuticals Inc and VisionGate Inc. RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose. This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors. Hardware/Software Requirements: Last review date: September 2015 |